{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 42,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/9",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Repotrectinib was approved November 2023; ** Not FDA approved, but in NCCN guidelines. 1L, 1st line; 2L, 2nd line; 3L, 3rd line; CNS, central nervous system. Sources (ALK): ... Sources (ROS1): ...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ad37a29-d96e-43cf-ab4d-10faa440e93c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.82,
        "x": 0.09,
        "y": 0.315
      },
      "kind": "table",
      "text": "Comparison of ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92c91c3d-1a86-4a2d-9073-62344924c6a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d1947ef-74af-4362-b45c-d49e45bfa4d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "ALK+ and ROS1+ NSCLC Landscape",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae083123-0760-4d10-a8b9-7112df80283e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "6c2b3747-97b7-4693-9bf7-5c16ca750801",
      "evidence": "table/data: Comparison of ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "b7452c1a-27c2-45ef-b9da-c8b367340d7b",
      "evidence": "Side-by-side comparison of two clinical landscapes",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "44f9f117-549b-472e-88fc-7cda82a56671",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents a clear problem statement on slide 9",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "65c3da30-3c59-494a-9036-da2194dedf71",
      "evidence": "The deck presents a clear pattern of limitations with current therapies and how Nuvalent's solution addresses them",
      "position": 0,
      "objective": "What are the limitations of current therapies and how does Nuvalent's solution address them?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}